FMP

FMP

Enter

SEEL - Seelos Therapeutics,...

photo-url-https://images.financialmodelingprep.com/symbol/SEEL.png

Seelos Therapeutics, Inc.

SEEL

NASDAQ

Inactive Equity

Seelos Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapeutics for the treatment of central nervous system, respiratory, and other disorders. The company's lead programs are SLS-002, an intranasal racemic ketamine for the treatment of acute suicidal ideation and behavior in patients with major depressive disorders; SLS-005, a protein stabilizer for the treatment of amyotrophic lateral sclerosis and Sanfilippo syndrome; and SLS-006, a partial dopamine agonist for the treatment of patients with Parkinson's disease (PD). Its preclinical programs include SLS-007, an anti-alpha-synuclein peptidic inhibitor to treat patients with PD; SLS-008, an orally available antagonist for chemoattractant receptor-homologous molecule for the treatment of chronic inflammation in asthma and pediatric orphan indications; SLS-004 for the treatment of PD; SLS-010, an oral histamine H3A receptor antagonist for narcolepsy and related disorders; and SLS-012, an injectable therapy for post-operative pain management. Seelos Therapeutics, Inc. was incorporated in 1987 and is headquartered in New York, New York.

0.37 USD

0 (0%)

Operating Data

Year

2020

2021

2022

2023

2024

2025

2026

2027

2028

2029

Revenue

-

-

-

-

-

-

-

-

-

-

Revenue %

-

-

-

-

-

-

-

-

-

Ebitda

-52.6M

-76.48M

-114.41M

-170.3M

-230.2M

-

-

-

-

-

Ebitda %

100

100

100

100

100

100

100

100

100

Ebit

-54.4M

-80.62M

-118.98M

-172.75M

-232.85M

-

-

-

-

-

Ebit %

100

100

100

100

100

100

100

100

100

Depreciation

1.81M

4.14M

4.58M

2.45M

2.65M

-

-

-

-

-

Depreciation %

100

100

100

100

100

100

100

100

100

Balance Sheet

Year

2020

2021

2022

2023

2024

2025

2026

2027

2028

2029

Total Cash

168.56M

476.3M

395.65M

583.39M

420.67M

-

-

-

-

-

Total Cash %

100

100

100

100

100

100

100

100

100

Receivables

2.96M

2.95M

3.06M

2.94M

4.92M

-

-

-

-

-

Receivables %

100

100

100

100

100

100

100

100

100

Inventories

-

-

-

-

-

-

-

-

-

-

Inventories %

100

100

100

100

100

100

100

100

100

Payable

3.43M

2.35M

3.73M

5.36M

2.58M

-

-

-

-

-

Payable %

100

100

100

100

100

100

100

100

100

Cap Ex

-6.54M

-2.39M

-2.34M

-2.27M

-5.66M

-

-

-

-

-

Cap Ex %

100

100

100

100

100

-

-

-

-

Weighted Average Cost Of Capital

Price

10.14

Beta

Diluted Shares Outstanding

66.57M

Costof Debt

4.42

Tax Rate

After Tax Cost Of Debt

4.42

Risk Free Rate

Market Risk Premium

Cost Of Equity

Total Debt

75.87M

Total Equity

675.02M

Total Capital

750.89M

Debt Weighting

10.1

Equity Weighting

89.9

Wacc

9.48

Build Up Free Cash Flow

Year

2020

2021

2022

2023

2024

2025

2026

2027

2028

2029

Revenue

-

-

-

-

-

-

-

-

-

-

Ebitda

-52.6M

-76.48M

-114.41M

-170.3M

-230.2M

-

-

-

-

-

Ebit

-54.4M

-80.62M

-118.98M

-172.75M

-232.85M

-

-

-

-

-

Tax Rate

-0.19

-0.19

-0.19

-0.19

-0.19

-0.19

-0.19

-0.19

-0.19

-0.19

Ebiat

-54.4M

-80.62M

-118.98M

-173.04M

-233.29M

-

-

-

-

-

Depreciation

1.81M

4.14M

4.58M

2.45M

2.65M

-

-

-

-

-

Receivables

2.96M

2.95M

3.06M

2.94M

4.92M

-

-

-

-

-

Inventories

-

-

-

-

-

-

-

-

-

-

Payable

3.43M

2.35M

3.73M

5.36M

2.58M

-

-

-

-

-

Cap Ex

-6.54M

-2.39M

-2.34M

-2.27M

-5.66M

-

-

-

-

-

Ufcf

-58.66M

-79.94M

-115.47M

-171.11M

-241.07M

2.34M

-

-

-

-

Wacc

9.48

9.48

9.48

9.48

9.48

Pv Ufcf

2.14M

0

0

0

0

Sum Pv Ufcf

2.14M

Terminal Value

Growth In Perpetuity Method

Long Term Growth Rate

Wacc

9.48

Free Cash Flow T1

0

Terminal Value

0

Present Terminal Value

0

Intrinsic Value

Enterprise Value

2.14M

Net Debt

1.41M

Equity Value

728.99k

Diluted Shares Outstanding

66.57M

Equity Value Per Share

0.01

Projected DCF

0.01095076 -924.963%

DCF Levered

Download Excel

FMP

FMP

Financial Modeling Prep API provides real time stock price, company financial statements, major index prices, stock historical data, forex real time rate and cryptocurrencies. Financial Modeling Prep stock price API is in real time, the company reports can be found in quarter or annual format, and goes back 30 years in history.
twitterlinkedinfacebookinstagram
2017-2024 © Financial Modeling Prep